Alexion Pharmaceuticals, Inc.’s Post

This #EarthDay, I'm proud of the efforts being made across AstraZeneca towards building a healthier future for people, society and the planet.    In BioPharmaceuticals we’re committed to reducing the environmental burden of care by driving improvements in patient outcomes as well as reducing the carbon footprint of our medicines.    Earlier detection of chronic diseases can help mitigate the burdens brought about by these illnesses. One example of how we are addressing this is through our ACT on CKD programme which aims to diagnose chronic kidney disease (CKD) in patients earlier to help reduce progression of CKD to kidney failure by 20% by 2025, ultimately reducing the carbon emissions and fresh water needed for haemodialysis and other intensive treatment.   And as part of our commitment to decarbonise respiratory care, we’re working to reduce the carbon footprint of our inhaled respiratory medicines by transitioning to next-generation propellants with near-zero global warming potential. Read more about the important work we are focussed on in our efforts to reduce our impact on the planet below:    https://lnkd.in/eCaAvgxE https://lnkd.in/eiU-ubdc

What an amazing way to close the year in which we celebrate our centenary… having our CEO Lars Fruergaard Jørgensen as person of the Year 2023 by Financial Times! Very proud of our journey as a company on behalf of the wellbeing of people living with serious chronic diseases! 💙 #novonordisk #drivingchangeforgenerations #novonordisk100

We don't inherit the earth from our ancestors. We only borrow it from our grandchildren. Yesterday was Earth Day. 🌎 Every day at AstraZeneca we are working to give everyone the chance to be as healthy as possible and that supporting a healthy environment is critical to the health of people, society and the planet. That’s why we’re integrating more circular approaches into the discovery, development and delivery of our medicines. ♻️ Together, we can build a healthier future #EarthDayV #PlanetVsPlastics https://lnkd.in/ebXzHvb7

"𝗠𝘆 𝘀𝗼𝗻 𝗕𝗲𝗻 is a normal boy with dreams and goals, 𝗷𝘂𝘀𝘁 𝗹𝗶𝗸𝗲 𝗬𝗼𝘂 𝗮𝗻𝗱 𝗺𝗲. His admirably positive mindset and his passion for art are what inspire me to drive for change in orphan drug development. Ben was born with Alström syndrome, an ultra-rare disease with 𝗻𝗼 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 available. Only 1,200 people globally have been diagnosed with it. Watching my son 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝘃𝗲𝗹𝘆 lose his eyesight and hearing is the most difficult thing I had to face in my entire life. Especially because there’s no doctor in the world who can do anything about it. We want to solve challenges in the World of rare diseases. Only talking is 𝘁𝗼𝗼 𝘄𝗲𝗮𝗸. Acting would be better. It’s all there - knowledge, technology, and money. The only limit is 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝘆. Let’s drive for change together!" Bernd Rosenbichler is one of five experts, who will speak at 𝗩𝗼𝗹𝘃'𝘀 𝗣𝗮𝗻𝗲𝗹 "𝘋𝘳𝘪𝘷𝘪𝘯𝘨 𝘧𝘰𝘳 𝘤𝘩𝘢𝘯𝘨𝘦 𝘪𝘯 𝘰𝘳𝘱𝘩𝘢𝘯 𝘥𝘳𝘶𝘨 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵" at the World Orphan Drug Congress. To learn more, follow future posts. #DriveForChange #RareDisease #WODC

Please let me share with you https://lnkd.in/gT5s8Kcg reflecting on how regulatory agencies, in the wake of #COVID are getting increasingly involved into accepting #RWD and #RWE to reach decision faster and with more accuracy. Really inspiring reading with access to various resources such as Darwin EU RWE data platform in Europe. #regulatoryaffairs #RWE #digitalhealth #publichealth #RWD #fda #emea

Excellent macro analysis of global landacape regarding RWE/RWD on decision-making and implications from safety, to regulatory environments and allocative efficiency considering therapeutic area/ population health maximization. Worth a read, the future is here in therapeutic access and sustainability!

Together, we can advance research and manufacturing for a healthier planet. Here's how - Transform healthcare with nucleic acid therapeutics - efficient, low-cost and green! #mRNA #oligotherapies #sustainability A good weekend read 📖🔖 https://cytiva.link/xxyje

Ready for Day #3 at World Orphan Drug Congress USA in Boston! 🔓 Today's Panel Discussion: "Unlocking Access: Transformative Policies and Strategies for Orphan Drug Accessibility" 🗣️ The EveryLife Foundation's Annie Kennedy highlights the critical steps for improving access: "We need to make sure we have the evidence collected early within the clinical trial ecosystem that then is available to payers to support access at the time of approval. We need to think about engaging with payers earlier." Ron Bartek Jayson Slotnik Heidi Ross Christoph Glaetzer, Dipl.Kfm. To learn more and check out the full agenda visit: https://lnkd.in/eBGXN8FE #raredisease #policy #WorldOrphanUSA

🌟 Breaking Barriers: Embracing the Moonshot Initiative in Rare Diseases! 🌙🚀 Exciting news for the rare disease community! We're thrilled to announce that Magda Chlebus, Executive Director Science Policy and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations (EFPIA), a visionary leader in healthcare innovation, will be presenting the groundbreaking Moonshot Initiative at the upcoming International Congress on Rare Diseases and Orphan Drugs. 🎤✨ Unveiling the Moonshot Initiative: 🚀 Mission: The Moonshot Initiative is a bold and transformative approach to addressing the challenges faced by the rare disease community. Magda Chlebus will unveil the mission, strategies, and collaborative efforts that make this initiative a beacon of hope for patients and caregivers. 🌈 Visionary Impact: Explore how the Moonshot Initiative aims to accelerate research, enhance patient care, and foster collaboration among stakeholders. Save the Date: [Friday 1st of March 09.20 – 10.00 AM] 🗓️ Digital How to Tune In: Secure your virtual seat now to witness this groundbreaking presentation. Register and be part of a transformative moment that could shape the future of rare disease interventions. 🔗 [Registrer here: https://bit.ly/3HkkWxA] Spread the Excitement: Tag your colleagues, fellow advocates, and anyone passionate about driving change in the rare disease landscape. Let's amplify the impact of the Moonshot Initiative together! #rarediseasesconference24 #MoonshotInitiative #RareDiseases #HealthcareInnovation #ICORD2023 #PatientAdvocacy Don't miss this extraordinary opportunity to be part of a paradigm-shifting conversation! 🌐🌟

Glad to have attended the 2024 NB Stroke Conference! 🧠🚑 Heart & Stroke NB | Coeur + AVC N.-B. Stroke management revolve around time and about 95% of stroke happens to occur outside hospital settings therefore immediate recognition is crucial. This has been easier using the FAST nemonic: F= Face drooping A= Arm weakness S= Speech difficulty T= Time to call 911 which should be FAST as well! Just a brief insight about the latest guidelines update regarding ischemic stroke management (2022): 🧠Initial CT and non invasive vascular imaging CTA or MRA should be obtained as soon as possible. 🧠 Initial blood work taken during time of resuscitation should include : RBG , CBC, RFT , Bleeding profile and ESR or CRP incase Gaint Cell Arterities is suspected ( pt presented with loss of vision or headache). 🧠All eligible patient with disabling stroke presenting within 4.5 hours( up to 6 hours in selected patients) from symptoms onset or last known well time should receive iv thrombolysis with either Alteplase (0.9 mg/kg with 10% given as bolus dose and 90% over the next 60 min) or the newest agent Tenecteplase (0.25mg/kg administered as one dose). 🧠All eligible patient presenting beyond 6 hours up to 24 hours should be assessed for endovascular thrombectomy (EVT). ⛔ REMEMBER TO ALWAYS BE IN A HURRY!!⛔🦸 Time is brain. Treatment benefits from revascularization decrease overtime and delay in stroke diagnosis and treatment can lead to the worst outcome. The ideal door-to-needle time is <60 min. Further information available at: https://lnkd.in/dHtqdsZZ